Acridine carboxamide
Jump to navigation
Jump to search
Overview
Acridine carboxamide (N-[(2'-dimethylamino)ethyl]acridine-4-carboxamide) is an chemotherapy agent that is being studied in the treatment of cancer. It belongs to the family of drugs called topoisomerase inhibitors.
While the agent was well-tolerated in Phase II clinical trials, it did not show efficacy when tested against various types of cancers.[1][2][3][4]
References
- ↑ Dittrich C, Dieras V, Kerbrat P; et al. (2003). "Phase II study of XR5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with advanced ovarian cancer". Investigational new drugs. 21 (3): 347–52. PMID 14578683.
- ↑ Caponigro F, Dittrich C, Sorensen JB; et al. (2002). "Phase II study of XR 5000, an inhibitor of topoisomerases I and II, in advanced colorectal cancer". Eur. J. Cancer. 38 (1): 70–4. PMID 11750842.
- ↑ Twelves C, Campone M, Coudert B; et al. (2002). "Phase II study of XR5000 (DACA) administered as a 120-h infusion in patients with recurrent glioblastoma multiforme". Ann. Oncol. 13 (5): 777–80. PMID 12075748.
- ↑ Dittrich C, Coudert B, Paz-Ares L; et al. (2003). "Phase II study of XR 5000 (DACA), an inhibitor of topoisomerase I and II, administered as a 120-h infusion in patients with non-small cell lung cancer". Eur. J. Cancer. 39 (3): 330–4. PMID 12565985.